Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 100,000 shares at $54.39 ($5.5M) on 2025-10-08, disclosed to the SEC on 2025-10-10.
Scheduled sale ($5.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.39 | 8,705 | $473K | 8.6% |
| 2 | $54.39 | 8,705 | $473K | 8.6% |
| 3 | $54.39 | 8,706 | $474K | 8.6% |
| 4 | $54.39 | 8,706 | $474K | 8.6% |
| 5 | $55.09 | 11,294 | $622K | 11.4% |
| 6 | $55.09 | 11,294 |
| $622K |
| 11.4% |
| 7 | $55.09 | 11,295 | $622K | 11.4% |
| 8 | $55.09 | 11,295 | $622K | 11.4% |
| 9 | $54.80 | 20,000 | $1.1M | 20.0% |
| Total | $54.79 avg | 100,000 | $5.5M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |